Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas. (August 2017)
- Record Type:
- Journal Article
- Title:
- Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas. (August 2017)
- Main Title:
- Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas
- Authors:
- Adem, Jemal
Eray, Mine
Eeva, Jonna
Nuutinen, Ulla
Pelkonen, Jukka - Abstract:
- Abstract: Antibodies produced by B-cells provide protection from infectious agents. However, impaired cell death signaling pathways in B-cells can lead to cancer, immunodeficiency or autoimmune diseases. B-cell signaling molecules such as CD20, CD19, Btk, and BAFF-R are targeted by therapeutic drugs and used to treat B-cell derived lymphomas or autoimmune diseases. Nevertheless, B-cells could develop resistance to these therapeutic drugs or the therapeutic drugs may have off-target effects. For instance, repeated rituximab (anti-CD20 antibody) treatment may lead to the loss of its target cell surface molecule, CD20. In addition, in B-cell malignancies, loss of CD19 expression has been observed. Another target molecule, Btk is expressed not only in B-cells but also in mast cells, macrophages, and dendritic cells. Thus, targeting Btk could negatively regulate the functions of innate immunity. The expression of BAFF-R is thought to be restricted to B-cells but it is also expressed on T-cells. Targeting BAFF-R, therefore, may lead to depletion of T-cells in addition to B-cells. B cell receptor (BCR) expression and signaling, however, are critically important for development, differentiation and survival of B-cells. Moreover, BCR is exclusively expressed on B-cells, which makes it an excellent target to avoid off-target effects.
- Is Part Of:
- Molecular immunology. Volume 88(2017:Aug.)
- Journal:
- Molecular immunology
- Issue:
- Volume 88(2017:Aug.)
- Issue Display:
- Volume 88 (2017)
- Year:
- 2017
- Volume:
- 88
- Issue Sort Value:
- 2017-0088-0000-0000
- Page Start:
- 135
- Page End:
- 137
- Publication Date:
- 2017-08
- Subjects:
- BCR -- Rituximab -- CD20 -- BAFF-R -- Autoimmune diseases -- Lymphoma
Immunochemistry -- Periodicals
Molecular biology -- Periodicals
Immunochemistry -- Periodicals
Allergy and Immunology -- Periodicals
Molecular Biology -- Periodicals
Immunochimie -- Périodiques
Biologie moléculaire -- Périodiques
Immunochemistry
Molecular biology
Periodicals
Electronic journals
571.96 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01615890 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.molimm.2017.05.023 ↗
- Languages:
- English
- ISSNs:
- 0161-5890
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5900.817700
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 2813.xml